Today, Lilly announced that Anat Ashkenazi, the company’s Chief Financial Officer (CFO), has resigned from her position to pursue a career opportunity outside the pharmaceutical industry.
David A. Ricks, the Chair and CEO of Lilly, expressed gratitude for Ashkenazi’s 23 years of dedicated service, particularly highlighting her significant contributions during her tenure as CFO. Under her leadership, the company experienced substantial growth and made advancements to expand patient access to Lilly’s medicines.
Before assuming the role of CFO, Ashkenazi served as Senior Vice President, Controller, and CFO of Lilly Research Laboratories. In this capacity, she oversaw financial operations across various sectors of the company, including commercial businesses, research and development, manufacturing and quality, and corporate strategy.
Ashkenazi will continue to fulfill her duties as CFO and as a member of Lilly’s Executive Committee until July 2024. The company has initiated both internal and external searches to find her successor.
About Lilly: Lilly is dedicated to transforming scientific breakthroughs into treatments that enhance lives globally. With a legacy spanning nearly 150 years, Lilly’s innovative medicines impact over 51 million individuals worldwide. Through biotechnology, chemistry, and genetic medicine, Lilly addresses pressing health challenges such as diabetes, obesity, Alzheimer’s disease, immune disorders, and cancer. The company prioritizes diversity in clinical trials and endeavors to ensure accessibility and affordability of its medicines.
Lilly’s Cautionary Statement Regarding Forward-Looking Statements: This press release contains forward-looking statements regarding leadership changes and future expectations. Actual results may vary due to various factors, including those outlined in Lilly’s latest filings with the Securities and Exchange Commission (SEC). The company advises against relying solely on forward-looking statements, which reflect only the date of this release, and disclaims any obligation to revise such statements post-release, except as required by law.
